Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Takeda Pharmaceutical Company Limited: Strengths and Weaknesses

  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Takeda Pharmaceutical Company Limited
  • The company appears to be poorly valued given its net asset value.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The company is one of the best yield companies with high dividend expectations.
Weaknesses: Takeda Pharmaceutical Company Limited
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • Low profitability weakens the company.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • With an expected P/E ratio at 39.95 and 24.19 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Most analysts recommend that the stock should be sold or reduced.

Rating Financials

Takeda Pharmaceutical Company Limited SectorJapan
Fundamentals
Growth
Revenue growth
EPS growth
FCF growth
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency
ROA
ROCE
ROE
Financial Health
Gearing
Leverage
Capital Intensity
Balance sheet growth
Long Term balance sheet growth
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

Takeda Pharmaceutical Company Limited SectorJapan
Global Valuation
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF
Equity Valuation
P/E
PBR
Dividend Yield
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

Takeda Pharmaceutical Company Limited SectorJapan
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Takeda Pharmaceutical Company Limited SectorJapan
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Takeda Pharmaceutical Company Limited SectorJapan
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
45.11B
AA
920B
A
510B
BBB
395B
AA
340B
AA
278B
A
254B
AAA
249B
A
224B
A
171B
A
Average 338.71B
AA
Weighted average by Cap.
AA
See all sector ratings
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. Ratings Takeda Pharmaceutical Company Limited